• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prostate cancer: Revealing mechanisms of resistance.

作者信息

Stone Louise

出版信息

Nat Rev Urol. 2018 Mar;15(3):138. doi: 10.1038/nrurol.2018.7. Epub 2018 Jan 23.

DOI:10.1038/nrurol.2018.7
PMID:29359738
Abstract
摘要

相似文献

1
Prostate cancer: Revealing mechanisms of resistance.前列腺癌：揭示耐药机制。
Nat Rev Urol. 2018 Mar;15(3):138. doi: 10.1038/nrurol.2018.7. Epub 2018 Jan 23.
2
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.在欧洲，对于之前接受醋酸阿比特龙联合泼尼松治疗≥24 周的转移性去势抵抗性前列腺癌患者，恩杂鲁胺的抗肿瘤活性和安全性。
Eur Urol. 2018 Jul;74(1):37-45. doi: 10.1016/j.eururo.2017.07.035. Epub 2017 Aug 23.
3
Androgen receptor-targeted agents in the management of advanced prostate cancer.雄激素受体靶向药物在晚期前列腺癌治疗中的应用
Lancet Oncol. 2019 Dec;20(12):1628-1630. doi: 10.1016/S1470-2045(19)30743-0.
4
Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.转移性去势抵抗性前列腺癌：针对醋酸阿比特龙和恩杂鲁胺的耐药机制
Expert Rev Anticancer Ther. 2015;15(9):1037-48. doi: 10.1586/14737140.2015.1063423. Epub 2015 Jul 1.
5
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.恩杂鲁胺联合醋酸阿比特龙治疗骨转移去势抵抗性前列腺癌患者。
Eur Urol Oncol. 2020 Feb;3(1):119-127. doi: 10.1016/j.euo.2019.01.008. Epub 2019 Apr 20.
6
Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.醋酸阿比特龙之后恩杂鲁胺的抗肿瘤活性及安全性：探寻去势抵抗性前列腺癌患者的最佳治疗顺序
Eur Urol. 2018 Jul;74(1):46-47. doi: 10.1016/j.eururo.2017.09.038. Epub 2017 Oct 21.
7
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.化疗初治转移性去势抵抗性前列腺癌患者接受恩杂鲁胺或醋酸阿比特龙治疗的治疗持续时间、医疗资源利用和成本：一项回顾性索赔分析。
Adv Ther. 2018 Oct;35(10):1639-1655. doi: 10.1007/s12325-018-0774-1. Epub 2018 Sep 6.
8
The third line of treatment for metastatic prostate cancer patients: Option or strategy?转移性前列腺癌患者的三线治疗：选择还是策略？
Crit Rev Oncol Hematol. 2015 Sep;95(3):265-71. doi: 10.1016/j.critrevonc.2015.04.010. Epub 2015 May 21.
9
Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer.病例报告：螺内酯撤药与转移性去势抵抗性前列腺癌患者的显著反应相关
Clin Genitourin Cancer. 2017 Feb;15(1):e95-e97. doi: 10.1016/j.clgc.2016.08.006. Epub 2016 Aug 10.
10
AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.循环肿瘤细胞簇中的AR-V7作为去势抵抗性前列腺癌患者醋酸阿比特龙和恩杂鲁胺治疗的预测生物标志物。
Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.

本文引用的文献

1
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).鉴定去势抵抗性前列腺癌（CRPC）患者对醋酸阿比特龙或恩杂鲁胺治疗产生耐药的机制。
Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19.